ACTR6
- Known as:
- ACTR6
- Catalog number:
- 001107A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- ACTR6
Related genes to: ACTR6
- Gene:
- ACTR6 NIH gene
- Name:
- actin related protein 6
- Previous symbol:
- -
- Synonyms:
- ARP6, FLJ13433
- Chromosome:
- 12q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-23
- Date modifiied:
- 2019-01-10
Related products to: ACTR6
Related articles to: ACTR6
- The liver is a common primary cancer site in humans. Actin-related protein 6 (ACTR6) plays a key role in liver cancer. The aim of this study was to further explore the regulatory molecular mechanism of ACTR6 in liver cancer. - Source: PubMed
Publication date: 2026/02/04
Jiao ChenweiZhu LichaoZhu AnzhiXu Xiaoqing - Hepatocellular carcinoma (HCC) is the third most prevalent cause of cancer-related mortality globally and the sixth most common cancer overall. It is critical to investigate new biomarkers and prognostic variables because there are currently no early diagnostic indicators. Actin-related proteins (ARPs) are involved in transcriptional regulation, chromatin remodeling, and DNA repair-all processes that have been connected to the development of cancer. However, it's still unclear how ARPs and HCC are related. - Source: PubMed
Publication date: 2025/03/10
Wang JingSong MengTang JinmingYue HaoranGuo XiaoyangChen ZhanShen XiaolanCao Mingbo - Osteosarcoma is generally considered a cold tumor and is characterized by epigenetic alterations. Although tumor cells are surrounded by many immune cells such as macrophages, T cells may be suppressed, be inactivated, or not be presented due to various mechanisms, which usually results in poor prognosis and insensitivity to immunotherapy. Immunotherapy is considered a promising anti-cancer therapy in osteosarcoma but requires more research, but osteosarcoma does not currently respond well to this therapy. The cancer immunity cycle (CIC) is essential for anti-tumor immunity, and is epigenetically regulated. Therefore, it is possible to modulate the immune microenvironment of osteosarcoma by targeting epigenetic factors. In this study, we explored the correlation between epigenetic modulation and CIC in osteosarcoma through bioinformatic methods. Based on the RNA data from TARGET and GSE21257 cohorts, we identified epigenetic related subtypes by NMF clustering and constructed a clinical prognostic model by the LASSO algorithm. ESTIMATE, Cibersort, and xCell algorithms were applied to analyze the tumor microenvironment. Based on eight epigenetic biomarkers (SFMBT2, SP140, CBX5, HMGN2, SMARCA4, PSIP1, ACTR6, and CHD2), two subtypes were identified, and they are mainly distinguished by immune response and cell cycle regulation. After excluding ACTR6 by LASSO regression, the prognostic model was established and it exhibited good predictive efficacy. The risk score showed a strong correlation with the tumor microenvironment, drug sensitivity and many immune checkpoints. In summary, our study sheds a new light on the CIC-related epigenetic modulation mechanism of osteosarcoma and helps search for potential drugs for osteosarcoma treatment. - Source: PubMed
Publication date: 2024/01/15
Yu BinGeng ChengkuiWu ZhongxiongZhang ZhongziZhang AiliYang ZeHuang JiazhengXiong YingYang HuiqinChen Zhuoyuan - Suicide is a societal and public health concern of global scale. Identifying genetic risk factors for suicide attempt can characterize underlying biology and enable early interventions to prevent deaths. Recent studies have described common genetic variants for suicide-related behaviors. Here, we advance this search for genetic risk by analyzing the association between suicide attempt and uncommon variation exome-wide in a large, ancestrally diverse sample. - Source: PubMed
Publication date: 2023/12/21
Wilkerson Matthew DHupalo DanielGray Joshua CZhang XijunWang JiaweiGirgenti Matthew JAlba CamilleSukumar GauthamanLott Nathaniel MNaifeh James AAliaga PabloKessler Ronald CTurner ClessonPollard Harvey BDalgard Clifton LUrsano Robert JStein Murray B - Breast cancer (BC) is the most common malignancy in women with high heterogeneity. The heterogeneity of cancer cells from different BC subtypes has not been thoroughly characterized and there is still no valid biomarker for predicting the prognosis of BC patients in clinical practice. - Source: PubMed
Publication date: 2022/09/01
Xu JieyunQin ShijieYi YunmengGao HanyuLiu XiaoqiMa FeiGuan Miao